topotecan has been researched along with hydroxyurea in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Berger, NA; Chatterjee, S; Cheng, MF | 1 |
| Annan, RS; Carr, SA; Chaturvedi, P; Eng, WK; Faucette, LF; Hurle, MR; Johnson, RK; Li, X; Lu, Q; Mattern, MR; Mishra, R; Scott, GF; Winkler, JD; Zhang, X; Zhou, BB; Zhu, Y | 1 |
| Battmer, K; Dammann, E; Eder, M; Ganser, A; Hambach, L; Heil, G; Hertenstein, B; Stucki, A | 1 |
| Chan, GC; Law, HK; Li, J; Liu, YL | 1 |
2 review(s) available for topotecan and hydroxyurea
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bone Marrow Transplantation; Combined Modality Therapy; Cyclosporine; Cystitis; Cytarabine; Cytomegalovirus Infections; DNA, Neoplasm; Female; Foscarnet; Ganciclovir; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Histocompatibility; Humans; Hydroxyurea; Immunosuppressive Agents; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Methotrexate; Mitoxantrone; Neoplasms, Second Primary; Prednisolone; Prostaglandins; Remission Induction; Topotecan; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2001 |
6 other study(ies) available for topotecan and hydroxyurea
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens.
Topics: Alkylating Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Aphidicolin; Camptothecin; Carmustine; Cell Cycle; Cell Death; Cell Line; Cisplatin; Cricetinae; Cricetulus; DNA Damage; DNA Repair; DNA, Neoplasm; Doxorubicin; Drug Synergism; Etoposide; Fibroblasts; Hydroxyurea; Lung; Melphalan; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 1994 |
Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway.
Topics: Alkylating Agents; Animals; Ataxia Telangiectasia Mutated Proteins; Cell Cycle; Cell Cycle Proteins; Cells, Cultured; Checkpoint Kinase 2; Cloning, Molecular; DNA Damage; DNA Repair; DNA-Binding Proteins; DNA, Complementary; DNA, Fungal; Enzyme Inhibitors; Fungal Proteins; Gamma Rays; Genetic Complementation Test; Humans; Hydroxyurea; Phosphorylation; Protein Kinases; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Proteins; ras-GRF1; Rats; Saccharomyces cerevisiae; Schizosaccharomyces; Schizosaccharomyces pombe Proteins; Signal Transduction; Species Specificity; Topoisomerase I Inhibitors; Topotecan; Tumor Suppressor Proteins | 1999 |
[Effect of cisplatin, topotecan, daunorubicin and hydroxyurea on human mesenchymal stem cells].
Topics: Antineoplastic Agents; Bone Marrow Cells; Cells, Cultured; Cisplatin; Daunorubicin; Humans; Hydroxyurea; Inhibitory Concentration 50; Mesenchymal Stem Cells; Topotecan | 2010 |